Drug intelligence / Profile preview

PB1018

Development stage: Preclinical
Lead developer: PEG Biosciences
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

PB1018 is an investigational immunotherapeutic biologic being developed by PEG Biosciences for the treatment of viral infections. The drug is engineered using the company's proprietary BioSynersys™ technology platform, which creates "Synergy PEG-enhanced" versions of biological drugs to improve their therapeutic profiles. PB1018 is designed to stimulate the host's immune response to combat viral pathogens. While it is a key candidate in PEG Biosciences' infectious disease pipeline, its specific molecular target and the identity of the underlying biological agent have not been publicly disclosed.

Beyond the preview

Go deeper on PB1018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB1018.

Explore the full profile